• Eligible patients with a diagnosis of aggressive NHL:

‣ Patients after progression on at least one standard chemotherapy and one salvage regimen or

⁃ Patients considered for alloSCT but are found ineligible or

⁃ Patients who have relapsed post alloSCT at least 100 days post-transplant, with no evidence of active GVHD, and no longer taking immunosuppressive agents for at least 30 days prior to enrollment.

• Patients with CNS disease (excluding isolated CNS lymphoma) are eligible only if disease has been successfully cleared at the time of inclusion.

• CD19 expression must be detected on the malignant cells by flow cytometry or immunohistochemistry

• Age \> 18 year up to 75 years old (if deemed fit by treating investigator);

• Baseline absolute CD3+ T cell count by FACS ≥100/µl;

• ECOG performance score of 0-2 at screening;

• No active Hepatitis B, Hepatitis C, HIV I/II

• No childbearing potential or negative pregnancy test at screening within 7 days from starting lymphodepletion chemotherapy and before bridging chemotherapy in women with childbearing potential;

• Signed and dated informed consent, before conduct of any trial-specific procedure.